Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-MVST Cells for Refractory Viral Infections in Transplant Recipients
NCT05183490Phase 1Recruiting
- Sponsor
- Columbia University
- Start
- May 2022
- Primary completion
- Jun 2028
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of rapidly generated virus specific T cells in Epstein-Barr virus infection, cytomegalovirus infection (CMV), adenovirus infection and 1 more (2 arms), sponsored by Columbia University. Primary endpoints: Incidence of toxicity that leads to safety endpoint at 28 days and Incidence of GVHD post-infusion that leads to safety endpoint at 28 days. Started May 2022; status: recruiting.
02
Drugs
rapidly generated virus specific T cells
03
Conditions
Epstein-Barr virus infectioncytomegalovirus infection (CMV)adenovirus infectionBK virus infection
Beyond the preview
Go deeper on NCT05183490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05183490.